Press Releases

Aribex Announces $200 Trade-Up Offer for Owners of Illegal Devices

OREM, Utah--(BUSINESS WIRE)-- Aribex®, Inc., the worldwide leader in handheld x-ray technologies, clarified that their Aribex NOMAD handheld x-ray devices are legal and not the subject of an investigation announced today by the U.S. Food and Drug Administration (FDA).

The FDA investigation involves the illegal online sales of handheld dental and veterinary x-ray units by manufacturers outside the United States. Aribex stressed that the NOMAD, which is manufactured in the United States, is proven safe, FDA-cleared, and approved for use in almost all states. Aribex officials said the company continues to have a positive working relationship with the FDA along with other state and local radiation safety officials.

“Clinician and patient safety has always been our number-one priority in developing and distributing our handheld x-ray device,” said Ken Kaufman, Aribex President and CFO, “and we are disappointed to learn that other manufacturers may not share a similar perspective. Just as the FDA fulfills its responsibilities, Aribex is equally committed to its role as the pioneer of safe and effective, battery-powered, handheld x-ray systems.”

“We support the FDA in their efforts to warn and protect, and we follow their message with one of our own: we ask dentists, hygienists, veterinarians and other certified radiation operators to understand that rapidly changing technology has made it possible for handheld x-ray systems to be both safe and effective. Not only is the NOMAD safe, patients and users have found that it improves their imaging experience.”

Aribex affirmed that each of their x-ray products meets FDA requirements, including FDA 510(K) clearance and labeling. Company officials said that numerous studies and evaluations have found the NOMAD to be safe, including the Washington State Department of Health study referenced by the FDA in today’s news release. Aribex maintains that their NOMAD systems are superior in their shielding and cone design characteristics when compared to any other intraoral dental x-ray system.

In response to challenges this may cause for U.S. dental and veterinary practices, Aribex is offering a $200 trade-up rebate on the purchase of a NOMAD to replace an illegal device. For more information on this rebate, affected practitioners should contact Aribex at 866-340-5522 or visit www.aribex.com.

About Aribex

Aribex is the worldwide leader in portable and handheld x-ray products. Aribex NOMAD x-ray systems are now in use in clinical, remote and mobile facilities throughout the world, from the finest professional offices to humanitarian missions reaching underserved populations who desperately seek care. The NOMAD significantly decreases costs and provides hundreds of safe, high-quality images for dental and veterinary applications on a single battery charge. For more information, visit www.aribex.com.

Aribex, Inc.Steve Dawson, 801-226-5522Marketing Managerwww.aribex.com

Source: Aribex, Inc.

TUCSON, AZ -- (MARKET WIRE) -- 02/10/12 -- CDEX Inc. (OTCBB: CEXI) today announced that to achieve a debt structure that would allow the Company to continue to develop its leading edge products in the healthcare markets with the ValiMed G4 medication safety system and in the security market with its ID2 Meth Scanner and Pocket ID2 Meth Scanner it has retained the law firm of Eric Slocum Sparks, P.C. to assist in the financial restructuring through the voluntary filing of a Chapter 11 reorganization in the United States Bankruptcy Court for the District of Arizona. During the restructuring, the Company intends to continue operating as normal, without interruption.

The Company's Board of Directors determined that Chapter 11 reorganization provides the most effective and efficient means to restructure with minimal impact on the business, and is in the best interest of the Company, its stakeholders and customers. "Although the Company has worked closely with its noteholders and other creditors and constituents over the past year, which led to the reduction of certain obligations, the Company needs to complete its comprehensive restructuring due to its current inability to negotiate restructuring terms with all noteholders," said Jeffrey Brumfield, Chairman and Chief Executive Officer of CDEX.

CDEX intends to file motions with the Court to ensure the Company's ability to continue its normal operations, including the ability to continue the development, sale and service of all of its products. The Company anticipates receiving approval from the Court within the next several days. "All forms of debt incurred prior to the commencement of the Company's Chapter 11 case that have not been paid is intended to be resolved through the Company's Plan of Reorganization," said Brumfield.

"Throughout this restructuring process, we are committed to working as quickly and efficiently as possible to appropriately restructure CDEX so that it can emerge from Chapter 11 as a strong company, well-positioned to compete effectively in the marketplace," continued Brumfield.

CDEX Inc. (CDEX) develops manufactures and distributes products for the healthcare and security markets. The company focuses its resources on marketing and improving real-time chemical detection products using patented technologies. CDEX creates reference signatures of substances of interest, such as selected narcotics, explosive compounds and medicines. CDEX primary area of focus is on products in the healthcare market and security markets. Its Healthcare Market line includes ValiMed" Medication Validation System (MVS) product line, which includes validation of substances, training and quality assurance. Its Security Market includes the ID2 Product Line, which comprise real time detection of specified illegal drugs in a portable handheld device.

Company contact:
Jeff Brumfield
(520) 745-5172
Email Contact

Source: CDEX Inc.